| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 272.0 | 258.9 |
| Profit before tax | 11.8 | -0.2 |
| Net income | 7.2 | -3.5 |
| EPS (diluted, $ a share) | $0.07 | $-0.05 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +5.0% |
|---|---|
| Operating margin | 10.3% |
10-Q filed with the SEC, NASDAQ: LMRI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Lumexa Imaging Holdings, Inc.: key numbers
- Share price
- $14.79Close, Nov 16
- Market cap
- $1.42B
- Shares outstanding
- 96.12MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Medical LaboratoriesSIC 8071
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Lumexa Imaging Holdings, Inc.
All →Lumexa Imaging Holdings Financial Results
Lumexa Imaging reported Q3 2026 financial results with revenue growing 5% to $272.0 million and net income of $7.2 million. The company reiterated its full-year revenue guidance while raising its Adjusted EPS outlook to $0.86–$0.90 due to a lower effective tax rate.
- Term
- Q3 2026
“In Q3, we advanced our business in several meaningful ways while executing against our strategy. Advanced modalities reached a record high as a percent of our volumes, and our newer de novo cohorts continue to ramp on plan. We are actively opening three new de novo centers and are on pace to achieve our goal for 8–10 new center openings this year.”
Caitlin Zulla, Chief Executive Officer of Lumexa Imaging
“We are leading a transformation in healthcare - delivering high-quality imaging in more convenient settings, more quickly and at meaningfully lower cost through our wholly owned centers and alongside health system partners, improving clinical and financial outcomes.”
Caitlin Zulla, Chief Executive Officer of Lumexa Imaging